Health Care·Biotechnology·$14.2B
BridgeBio Pharma Inc is a biotechnology company focused on developing therapies for genetic diseases. With a market cap of $14 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs through innovative treatments.
EPS (Earnings Per Share)
EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.
Revenue
Although revenue estimates are not available, any reported figures will provide insight into the company's market performance and product uptake.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
50%
Avg EPS Surprise
+5.62%
Avg Stock Reaction
+0.95%
In Q4 2025, BridgeBio reported an EPS of -$1.00, which was worse than analysts' expectations. The stock reacted positively, gaining 0.59% the following day.
Management Promises & Guidance
Overall, expectations for BridgeBio's upcoming earnings are cautious, given the recent history of EPS misses. Investors are looking for any signs of improvement in financial performance.
Bull Case
If the company can demonstrate a smaller loss than expected and provide positive updates on its drug pipeline, it could boost investor confidence and drive the stock higher.
Bear Case
Conversely, if the company reports larger losses or fails to provide clarity on its future prospects, it could lead to a negative reaction from the market.
EPS (Earnings Per Share)
$-1.00EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.
Revenue
N/AAlthough revenue estimates are not available, any reported figures will provide insight into the company's market performance and product uptake.
R&D Expenses
N/AResearch and Development expenses will indicate the company's commitment to innovation and future growth potential.
The print will turn on these two things.
Q1
What is the expected EPS for Q1 2026, and how does it compare to previous quarters?
The EPS figure will be crucial in assessing the company's financial health and performance against market expectations.
Q2
What updates can management provide on the progress of their drug pipeline?
Investors will be keen to understand the status of key therapies in development, as this will impact future revenue potential.
Why consensus could be wrong
The market may be underestimating BridgeBio's potential for a smaller-than-expected EPS loss due to recent operational improvements and pipeline advancements.
Supporting Evidence
The company has a history of surprising the market positively despite recent losses.
Management's focus on strategic partnerships may yield better-than-expected results.
Recent advancements in their drug pipeline could lead to improved market sentiment.
Key Risk
If the EPS loss comes in below $0.90, it could challenge the current bearish consensus.
Pre-commit to what would confirm each case.
This quarter's results will be pivotal in determining whether BridgeBio can stabilize its financial performance and regain investor confidence.
Bull Confirmed If
A reported EPS loss of less than $0.90 would confirm the bull case and suggest improving financial health.
Bear Confirmed If
An EPS loss greater than $1.10 would confirm the bear case and raise concerns about the company's viability.
Implied Move
±N/A
There is currently no options market data available to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If BridgeBio beats EPS expectations, history suggests the stock could rise by around 2% on the following day, confirming a positive trend.
In-Line / Cautious
If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors wait for clearer signals.
Miss
Should the company miss expectations, history indicates a potential decline of about 2.09% in the stock price, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026